SEC Form 4 · accession 0001237899-15-000028
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A Baker
Director
Period of report
Mar 25, 2015
Accepted (ET)
Mar 26, 2015 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 25, 2015 | M | 5,000 | $18.61 | A | 14,000 | D | |
| Common Stock | Mar 25, 2015 | S | 300 | $452.45 | D | 13,700 | D | |
| Common StockF2 | Mar 25, 2015 | S | 265 | $453.71 | D | 13,435 | D | |
| Common StockF3 | Mar 25, 2015 | S | 1,999 | $454.38 | D | 11,436 | D | |
| Common StockF4 | Mar 25, 2015 | S | 1,536 | $455.48 | D | 9,900 | D | |
| Common StockF5 | Mar 25, 2015 | S | 700 | $456.36 | D | 9,200 | D | |
| Common StockF6 | Mar 25, 2015 | S | 200 | $457.21 | D | 9,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F7 | $18.61 | Mar 25, 2015 | M | 5,000 | D | — | Jan 2, 2019 | Common Stock | 5,000 | 10,000 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2Represents volume-weighted average price of sales of 265 shares of Company stock on March 25, 2015 at prices ranging from $453.33 to $453.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 25, 2015 at each separate price.
- F3Represents volume-weighted average price of sales of 1,999 shares of Company stock on March 25, 2015 at prices ranging from $454.03 to $454.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 25, 2015 at each separate price.
- F4Represents volume-weighted average price of sales of 1,536 shares of Company stock on March 25, 2015 at prices ranging from $455.00 to $455.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 25, 2015 at each separate price.
- F5Represents volume-weighted average price of sales of 700 shares of Company stock on March 25, 2015 at prices ranging from $456.00 to $456.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 25, 2015 at each separate price.
- F6Represents volume-weighted average price of sales of 200 shares of Company stock on March 25, 2015 at prices ranging from $457.00 to $457.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 25, 2015 at each separate price.
- F7The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.